There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (BGNE – Research Report) and Dyne Therapeutics (DYN – Research Report) with bullish sentiments.
BeiGene (BGNE)
In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on BeiGene, with a price target of $414.00. The company’s shares closed last Wednesday at $356.41.
According to TipRanks.com, Berens is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeiGene with a $417.33 average price target.
See today’s best-performing stocks on TipRanks >>
Dyne Therapeutics (DYN)
Jefferies analyst Eun Yang maintained a Buy rating on Dyne Therapeutics yesterday and set a price target of $47.00. The company’s shares closed last Wednesday at $14.88, close to its 52-week low of $13.50.
According to TipRanks.com, Yang is a 4-star analyst with an average return of
Currently, the analyst consensus on Dyne Therapeutics is a Moderate Buy with an average price target of $40.50, representing a 173.5% upside. In a report issued on October 1, Piper Sandler also maintained a Buy rating on the stock with a $34.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BGNE:
- Analysts Offer Insights on Financial Companies: First Republic Bank (FRC) and JPMorgan Chase & Co. (JPM)
- Wall Street Analysts Are Bullish on Top Services Picks
- Plug Power Partners With Airflow to Develop Hydrogen-Based Propulsion System; Shares Pop 13%
- Noble Financial Reaffirms Their Buy Rating on Great Lakes Dredge & Dock (GLDD)
- Industrial Tech Acquisitions (ARBE) Receives a Buy from R.F. Lafferty
